GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Teva Pharmaceutical Industries TEVA.TA · ILA

Health Care · Tel Aviv · 🇮🇱 Israel

Compare

13,580.00

+2.11%

Close of 9 Nov 2026, in ILA

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$18.68bn

FY2016FY2025

Net income

$1.53bn

FY2016FY2025

Free cash flow

$2.56bn

FY2016FY2025

Shareholders' equity

$7.91bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$18.68bn$16.54bn$15.85bn$14.93bn$15.88bn$16.66bn$16.89bn$18.85bn$22.39bn$21.90bn
Gross profit$9.63bn$8.06bn$7.65bn$6.97bn$7.59bn$7.72bn$7.54bn$8.30bn$10.82bn$11.86bn
Research and development$1.10bn$998.0m$1.04bn$838.0m$967.0m$997.0m$1.01bn$1.21bn$1.85bn$2.11bn
Operating income$4.28bn−$303.0m$433.0m−$2.10bn$1.62bn−$3.44bn−$443.0m−$1.61bn−$17.50bn$1.37bn
Net income$1.53bn−$1.64bn−$559.0m−$2.35bn$417.0m−$3.99bn−$999.0m−$2.15bn−$16.27bn$329.0m
Diluted earnings per share1.30-1.45-0.50-2.120.38-3.64-0.91-2.09-15.990.32

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$40.76bn$39.33bn$43.48bn$44.01bn$47.67bn$50.64bn$57.47bn$60.68bn$70.61bn$92.89bn
Cash and short-term investments$3.56bn$3.30bn$3.23bn$2.80bn$2.17bn$2.18bn$1.98bn$1.78bn$963.0m$988.0m
Total liabilities$32.84bn$33.61bn$35.35bn$35.31bn$36.42bn$39.58bn$42.41bn$44.89bn$51.87bn$57.90bn
Debt$17.39bn$18.08bn$20.15bn$21.56bn$23.46bn$26.40bn$27.34bn$28.92bn$32.48bn$35.80bn
Shareholders' equity$7.91bn$5.37bn$7.51bn$7.90bn$10.28bn$10.03bn$13.97bn$14.71bn$17.36bn$33.34bn
Shares outstanding1,173m1,133m1,121m1,111m1,103m1,095m1,094m1,031m1,017m1,015m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$3.10bn$1.25bn$1.37bn$1.59bn$798.0m$1.22bn$538.0m$2.45bn$3.51bn$5.22bn
Capital spending−$542.3m−$498.0m−$526.0m−$548.0m−$562.0m−$578.0m−$119.0m−$651.0m−$874.0m−$901.0m
Free cash flow$2.56bn$749.0m$842.0m$1.04bn$236.0m$638.0m$419.0m$1.79bn$2.63bn$4.32bn
Dividends paid——————−$52.0m−$22.0m−$1.16bn−$1.56bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$4.14bn$3.97bn$4.81bn$4.48bn$4.18bn$3.89bn$4.23bn$4.33bn
Gross profit$2.15bn$1.97bn$2.70bn$2.30bn$2.10bn$1.88bn$2.12bn$2.15bn
Operating income$167.0m$652.0m$363.9m$882.0m$455.0m$519.0m−$29.0m−$51.0m
Net income−$576.0m$370.0m$489.9m$433.0m$282.0m$214.0m−$217.0m−$437.0m
Diluted earnings per share-0.490.320.420.370.240.18-0.19-0.39
Cash from operations$721.0m$313.0m$1.53bn$369.0m$227.0m−$105.0m$575.0m$693.0m
Capital spending−$101.0m−$167.0m−$146.0m−$136.0m−$96.0m−$127.0m−$129.0m−$148.0m
Free cash flow$620.0m$146.0m$1.38bn$233.0m$131.0m−$232.0m$446.0m$545.0m
Total assets$39.86bn$40.43bn$40.76bn$39.86bn$40.13bn$38.41bn$39.33bn$41.76bn
Cash and short-term investments$3.63bn$3.78bn$3.56bn$2.20bn$2.16bn$1.70bn$3.30bn$3.32bn
Debt$16.56bn$16.65bn$16.81bn$16.79bn$17.23bn$16.65bn$17.78bn$18.98bn
Shareholders' equity$7.75bn$8.31bn$7.91bn$7.25bn$6.83bn$6.26bn$5.37bn$6.07bn

Financial ratios

Data as of 19 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin51.6%48.7%48.3%46.7%47.8%46.4%
Operating margin22.9%-1.8%2.7%-14.1%10.2%-20.7%
Net margin8.2%-9.9%-3.5%-15.8%2.6%-24.0%
Return on equity19.3%-30.5%-7.4%-29.8%4.1%-39.8%
Return on assets3.7%-4.2%-1.3%-5.3%0.9%-7.9%
Free cash flow yield0.0%0.0%0.0%0.0%0.0%0.0%
Revenue growth12.9%4.4%6.2%-6.0%-4.7%-1.4%
Earnings growth-193.2%193.2%-76.2%-664.3%-110.5%299.4%
Current ratio1.04x0.98x1.02x1.05x1.14x0.99x
Debt to equity2.12x3.33x2.66x2.70x2.25x2.60x
Equity ratio19.4%13.7%17.3%17.9%21.6%19.8%
Interest coverage4.23x-0.30x0.42x-2.17x1.53x-3.58x
R&D as a share of sales5.9%6.0%6.6%5.6%6.1%6.0%
Buybacks as a share of market value-3.5%-1.1%-0.9%-0.7%-0.7%-0.1%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue7.8%2.3%-0.5%
Operating income——2.5%
Net income——-0.4%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin50.2%49.0%48.3%49.2%
Operating margin11.3%3.5%0.5%-7.2%
Net margin-0.3%-4.6%-6.7%-12.2%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings26.0-18.8-25.9-5.223.9-2.8
Price to sales2.11.90.90.80.60.7

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 28 Nov 2017.

FY2017FY2016FY2015FY2014FY2013FY2012FY2011FY2010
Paid in the year3.1055.375.2484.844.604.003.202.80

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.